TGFβR2-expressing and TGFβR2-negative CAFs have also been shown to facilitate metastatic progression, and have been observed in both primary and metastatic prostate cancer clinical specimens [104,156,237]. The gene discussed is TGFBR2; the disease is metastatic prostate carcinoma.